Breaking news

X Shifts U.S. Creator Payouts To X Money With No Minimum Threshold

X said Wednesday that all creator payouts in the U.S. will now be processed through X Money, its payments service, with the change taking effect immediately.

The new system covers earnings from X’s Original Content Rewards Program and creator subscriptions, according to X Creators. U.S. creators will receive access to their funds as soon as payouts are sent, the company said.

Instant Access Replaces Biweekly Payouts

Previously, X paid creators every two weeks and required them to earn at least $30 before receiving a payout, according to the company’s documentation.

Under X Money, creators no longer need to wait for the end of a billing cycle or meet a minimum threshold. The faster access could be particularly useful for independent publishers and smaller creators who rely on regular payments for operating expenses.

U.S. Creators Must Switch From Stripe

The change is mandatory for creators in the U.S. Those previously receiving payments through Stripe will have to move to X Money, an X representative confirmed. Creators outside the U.S. will continue receiving payouts through Stripe.

X Reshapes Creator Monetization

The payments change comes as X prepares to retire its Creator Revenue Sharing Program on Sept. 7. The program stopped accepting new members last month, and creators are being moved to the Original Content Rewards Program, which emphasizes original content.

The shift is part of X’s broader effort to restructure creator monetization around content produced for the platform.

X Money Expands Musk’s Payments Strategy

X Money, which began supporting creator payouts earlier this month, is part of Elon Musk’s effort to turn X into an “everything app.”

The service offers a bank card with 3% cash back, instant payments, free ATM withdrawals and other digital banking features. X Money is not a bank, however. Customer accounts are held at Cross River Bank, an FDIC-insured institution.

Payouts Also Affect Interest And Tax Reporting

Creator payouts will count toward the direct deposit requirements for X Money’s higher APY rate. According to X Money’s interest FAQ, X Premium users can receive a 6% rate, compared with 4% for the standard rate.

X said it will issue a 1099-NEC to individuals receiving creator payouts. For LLCs, the company will collect W-9 information for tax reporting purposes.

Medochemie And Theramir Announce Strategic Investment Agreement To Advance Biotech Manufacturing In Cyprus

Pharmaceutical manufacturer Medochemie and biotechnology company Theramir, both Cyprus-based, have announced a strategic investment agreement and collaboration aimed at developing next-generation biological therapies and expanding manufacturing capabilities in Cyprus.

The agreement, announced on 2 September 2026, brings together Medochemie’s experience in pharmaceutical manufacturing and Theramir’s biotechnology research. The companies said the collaboration would support advanced pharmaceutical manufacturing in Cyprus and south-eastern Europe.

What The Partnership Covers

Medochemie’s contribution will include its expertise in manufacturing sterile therapeutic products and its access to international markets.

Theramir develops technologies based on extracellular vesicles and microRNAs. Its work includes using stem-cell-derived extracellular vesicles to deliver microRNAs, small, non-coding RNA molecules that regulate genes and biological pathways associated with cancer growth and metastasis.

Under the agreement, the companies will jointly support the development of “Good Manufacturing Practice” capabilities for next-generation biological therapies. The partnership is also intended to help move these therapies towards clinical development.

A Wider Role For Cyprus

The collaboration will also support Theramir’s wider research programme. According to the companies, it is intended to strengthen Cyprus’s biotechnology infrastructure and expand local capacity in next-generation biomanufacturing.

They present the agreement as a step towards giving Cyprus a larger role in biotechnology and advanced pharmaceutical manufacturing for south-eastern Europe and international markets.

eCredo
Uol
Aretilaw firm
The Future Forbes Realty Global Properties

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter